Rational design of orally-active, pyrrolidine-based progesterone receptor partial agonists.
Thompson, S.K., Washburn, D.G., Frazee, J.S., Madauss, K.P., Hoang, T.H., Lapinski, L., Grygielko, E.T., Glace, L.E., Trizna, W., Williams, S.P., Duraiswami, C., Bray, J.D., Laping, N.J.(2009) Bioorg Med Chem Lett 19: 4777-4780
- PubMed: 19595590 
- DOI: https://doi.org/10.1016/j.bmcl.2009.06.055
- Primary Citation of Related Structures:  
3G8O, 3HQ5 - PubMed Abstract: 
Using the X-ray crystal structure of an amide-based progesterone receptor (PR) partial agonist bound to the PR ligand binding domain, a novel PR partial agonist class containing a pyrrolidine ring was designed. Members of this class of N-alkylpyrrolidines demonstrate potent and highly selective partial agonism of the progesterone receptor, and one of these analogs was shown to be efficacious upon oral dosing in the OVX rat model of estrogen opposition.
Organizational Affiliation: 
Department of Chemistry, Metabolic Pathways Centre for Excellence in Drug Discovery, GlaxoSmithKline Pharmaceuticals, 709 Swedeland Road, King of Prussia, PA 19406, USA.